Formycon Delay Pushes Back Coherus’ Ranibizumab

FDA Requests Additional Data On Lucentis Rival

Formycon and Bioeq’s US filing for a biosimilar ranibizumab rival to Lucentis has been delayed after the FDA requested further data following a manufacturing change. Rights to the biosimilar have been licensed exclusively to Coherus in the US.

Delayed
Formycon and Bioeq's US Ranibizumab Application Has Been Delayed • Source: Shutterstock

Formycon has announced that its US filing for its FYB201 ranibizumab biosimilar has been delayed by several months, after the US Food and Drug Administration asked the firm and its licensing partner Bioeq for more information on the application following a manufacturing change.

Coherus BioSciences had recently struck a deal to acquire exclusive rights from Bioeq to commercialize the biosimilar rival to...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.